Novo Nordisk Focuses on Raising the Bar in Research in 2018
In the diabetes care segment, the company is currently focused on developing insulin and glucagon-like peptide 1 (or GLP-1) products, which demonstrate distinct clinical advantages in terms of factors such as the absence of hypoglycemia, reduced comorbidity risk related to cardiovascular events, and weight loss. Novo Nordisk is also evaluating new treatment options with improved delivery mechanisms, such as oral delivery. The above diagram shows the evolution of Novo Nordisk’s insulin and GLP-1 franchises since 1923 and 1986, respectively.